COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,557 Articles (22,400 medRxiv, 8,157 bioRxiv)

Most recent first Previous |  Page 1189: Articles 11881-11890  | Next

Combining antibody markers for serosurveillance of SARS-CoV-2 to estimate seroprevalence and time-since-infection
Bhuiyan, M. S., Brintz, B. J., Whitcombe, A. L., Markmann, A., Bartelt, L., Moreland, N. J., Azman, A., Leung, D.
10.1101/2021.09.06.21261175 — Posted: 2021-09-08
Landscape of SARS-CoV-2 genomic surveillance, public availability extent of genomic data, and epidemic shaped by variants: a global descriptive study
Chen, Z., Azman, A., Chen, X., Zou, J., Tian, Y., Sun, R., Xu, X., Wu, Y., Lu, W., Ge, S., Zhao, Z., Yang, J., Leung, D., Domman, D., Yu, H.
10.1101/2021.09.06.21263152 — Posted: 2021-09-08
Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomized controlled trial
Bonelli, M., Mrak, D., Tobudic, S., Sieghart, D., Koblischke, M., Mandl, P., Kornek, B., Simader, E., Radner, H., Perkmann, T., Haslacher, H., Mayer, M., Hofer, P., Redlich, K., Husar-Memmer, E., Fritsch-Stork, R., Thalhammer, R., Stiasny, K., Winkler, S., Smolen, J. S., Aberle, J. H., Zeitlinger, M., Heinz, L. X., Aletaha, D.
10.1101/2021.09.05.21263125 — Posted: 2021-09-08
Entrectinib - a SARS-CoV-2 inhibitor in Human Lung Tissue (HLT) cells
Peralta-Garcia, A., Torrens-Fontanals, M., Stepniewski, T. M., Grau-Exposito, J., Perea, D., Ayinampudi, V., Waldhoer, M., Zimmermann, M., Buzon, M. J., Genesca, M., Selent, J.
10.1101/2021.09.07.459123 — Posted: 2021-09-07
SARS-CoV-2 originated from SARS-CoV-1-related Bat-CoVs through Pan-CoVs rather than from SARS-CoV-2-related Bat-CoVs
Desingu, P. A., Nagarajan, K.
10.1101/2021.09.06.459210 — Posted: 2021-09-07
Ineffective neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine sera
Uriu, K., Kimura, I., Shirakawa, K., Takaori-Kondo, A., Nakada, T.-a., Kaneda, A., The Genotype to Phenotype Japan (G2P-Japan) Consortium, , Nakagawa, S., Sato, K.
10.1101/2021.09.06.459005 — Posted: 2021-09-07
Increased neutralization of SARS-CoV-2 Delta variant by nanobody (Nb22) and the structural basis
Wu, X., Wang, Y., Cheng, L., Zhu, L., Ma, S., Huang, B., Xu, S., Shi, H., Liu, L., Nawaz, W., Ye, S., Wu, Z.
10.1101/2021.09.06.459055 — Posted: 2021-09-07
The vaccinia-based Sementis Copenhagen Vector COVID-19 vaccine induces broad and durable cellular and humoral immune responses
Eldi, P., Cooper, T. H., Prow, N. A., Liu, L., Heinemann, G. K., Zhang, V. J., Trinidad, A. D., Guzman-Genuino, R. M., Wulff, P., Hobbs, L. M., Diener, K. R., Hayball, J. D.
10.1101/2021.09.06.459206 — Posted: 2021-09-07
Durability analysis of the highly effective BNT162b2 vaccine against COVID-19
Puranik, A., Lenehan, P., O'Horo, J. C., Niesen, M. J., Virk, A., Swift, M. D., Kremers, W., Venkatakrishnan, A., Gordon, J. E., Geyer, H. L., Speicher, L. L., Soundararajan, V., Badley, A. D.
10.1101/2021.09.04.21263115 — Posted: 2021-09-07
Both Simulation and Sequencing Data Reveal Multiple SARS-CoV-2 Variants Coinfection in COVID-19 Pandemic
Li, Y., Jiang, Y., Li, Z., Yu, Y., Chen, J., Jia, W., Ng, Y. K., Ye, F., Shen, B., Li, S. C.
10.1101/2021.09.06.459196 — Posted: 2021-09-07

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).